Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
47 hedge funds and large institutions have $47M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
4% more funds holding
Funds holding: 45 → 47 (+2)
45% less capital invested
Capital invested by funds: $85.9M → $47M (-$38.9M)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
94% less call options, than puts
Call options by funds: $1K | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.32M |
| 2 |
Renaissance Technologies
New York
|
+$527K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$278K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$139K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$80.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.99M |
| 2 |
BlackRock
New York
|
-$2.53M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$679K |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$525K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$430K |
NBRV Hedge Fund Activity: Q4 2018 in Review
47 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2018, worth a combined $47M — down 45% from $85.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NBRV positions and 9 closed out — a net gain of 2 holders — while 7 added to existing stakes and 17 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.32M. The largest seller was Wellington Management Group, cutting an estimated $2.99M.
- 47 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2018, up from 45 in Q3 2018.
- Funds reported $47M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2018, down 45% quarter-over-quarter.
- 11 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2018 and 9 closed out, a net change of +2 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2018 was Fidelity Investments, an estimated $3.32M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2018 was Wellington Management Group, an estimated $2.99M sold.
Based on aggregated 13F filings for Q4 2018.